35^th World Pharmacology and Toxicology Forum September 21-22, 2020 Tokyo, Japan

Vuong Trieu, Ph.D. is the founder and chairman of Oncotelic and was appointed to the Company’s Board and to serve as Chairman of the Board and CEO of Mateon in connection with the Merger with Oncotelic. Dr. Trieu is an expert is drug repositioning with several high profile successes including Abraxane and Cynviloq- both are billion dollar drugs. He is leading Mateon effort to become the next generation pharmaceutical by leveraging AI data analytics to create a high value pipeline. You don’t know what you don’t know- but there is no excuse for not knowing.

Nanomedicine and Oncology

Dr. Kinjal Pragnesh Solanki has completed her PhD in 2017 from Bhagwant University, India and M.Pharm from Ganpat University, India. She is the Associate Professor in Shankersinh Vaghela Bapu Institute of Pharmacy, India. She has published more than 25 papers in reputed journals and has been advisory member in many professional bodies.

Pharmacology and Toxicology

Dr. Ralph Brückner has a strong interest for the interaction of chemistry with biological systems that has lead him through an exciting journey from Medicinal Chemistry to modern Hygiene. He has achieved his PHD at the university of Würzburg on the metabolic fate and neurotoxic behaviour of (14C)TaClo, an endogenously formed ß-carbolin. As post doc he moved to the research Center Jülich where he established one of the first hypenations of ion chromatography with mass spectrometry for the elucidation of Krebs-cyle metabolites in bacteria. From there he received a call to follow the new team of medicinal chemistry department of Boehringer Ingelheim in Vienna (Austria). As head of laboratory he was reponsible for PK/PD in the thrilling field of oncology for 8 years. Since 2016 he works within the HECOSOL GmbH as head of R&D on the development of antimicrobial surfaces in sensitive areas of the medical sector and the food industry. The intention is to reduce hospital acquired infection diseases by a permanent reduction of pathogenic germs.

ADME, Drug Discovery

Mr. Sinha received his Bachelors of Science (BS) and Master of Science (MS) degrees in Bacteriology / Natural Science from the University of Wisconsin – Madison, Wisconsin, USA. He completed his Master’s in Business Administration (MBA) from the New York Institute of Technology, New York, USA. Kuntal Sinha has been in the Pharmaceutical industry for over 25 years. His experience over the years have spanned within the Contract Research Organization (CRO) and pharmaceutical companies. At Covance, Mr. Sinha’s responsibility included research supporting Metabolic Chemistry and Drug Metabolism Since 2016, Mr. Sinha has been managing the activities associated with pharmacovigilance and clinical trial safety and serves as an advisory / consultative capacity in compliance related safety matters. More recently, Mr. Sinha is Director at Alkermes within Clinical Quality Assurance group supporting pharmacovigilance, Medical Affairs and Commercial Organization on drug safety related to adverse events and product complaints.

Clinical Trails